Australia's Clarity Pharmaceuticals rises on nod to begin prostate cancer trial

Clarity Pharmaceuticals

04/07/2023 04:32

** Shares of Clarity Pharmaceuticals  CU6.AX  rise as much
as 4.1% to A$0.77, their highest since June 28
    ** Radio-pharmaceuticals co says it has gained U.S. FDA
approval to begin a phase three trial called CLARIFY, assessing
its 64Cu SAR-bisPSMA diagnostic in prostate cancer
    ** Co says it expects to begin patient recruitment for the
trial in late 2023 
    ** Says new trial will treat patients with high-risk
prostate cancer before receiving a radical prostatectomy
    ** Stock down 25.3% YTD as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))